Search

Displaying results 9141 - 9150 of 10000 in total
  1. Drug

    Opipramol

    go.drugbank.com/drugs/DB12930
    Investigational

    Opipramol has been used in trials studying the treatment of Dementia, Depression, Schizophrenia, Anxiety Disorders, and Psychosomatic Disorders.

  2. Drug

    VS-5584

    go.drugbank.com/drugs/DB12986
    Investigational

    VS-5584 has been used in trials studying the treatment of Lymphoma, Metastatic Cancer, and Non Hematologic Cancers.

  3. Drug

    Penclomedine

    go.drugbank.com/drugs/DB12987
    Investigational

    Penclomedine has been used in trials studying the treatment of Lymphoma and Unspecified Adult Solid Tumor, Protocol Specific.

  4. Drug

    Icosabutate

    go.drugbank.com/drugs/DB12990
    Investigational

    Icosabutate is under investigation in clinical trial NCT02373176 ([14C] Icosabutate -A Phase I Absorption, Metabolism and Excretion Study).

  5. Drug

    Pyritinol

    go.drugbank.com/drugs/DB13084
    Investigational

    Pyritinol has been used in trials studying the treatment of Dementia, Depression, Schizophrenia, Anxiety Disorders, and Psychosomatic Disorders.

  6. Drug

    Ibezapolstat

    go.drugbank.com/drugs/DB16189
    Investigational

    Ibezapolstat is under investigation in clinical trial NCT04247542 (ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile Infection).

  7. Drug

    Izencitinib

    go.drugbank.com/drugs/DB16660
    Investigational

    Izencitinib is under investigation in clinical trial NCT03920254 (TD-1473 Long-term Safety (LTS) Ulcerative Colitis (UC) Study).

  8. Drug

    NGN-101

    go.drugbank.com/drugs/DB18335
    Investigational

    NGN-101 is an adeno-associated virus serotype 9 vector with engineered transgene encoding the human CLN5 gene

  9. Drug

    ECT204

    go.drugbank.com/drugs/DB18605
    Investigational

    ECT204 is an autologous T-cell therapy whereby T cells are genetically modified to target tumor-specific antigens.

  10. Drug

    Prosetin

    go.drugbank.com/drugs/DB18649
    Investigational

    Prosetin is an orally administered blocker of MAP4K under investigation for the treatment of amyotrophic lateral sclerosis.[L48360]